PRTAProthena Corporation plc Ordinary Shares

CSNasdaq (XNAS)·USD

Identity

Security key: 20373
Ticker: PRTA
Type: CS — Common Stock
Exchange: Nasdaq(XNAS)
Venue group: NASDAQ
Operating MIC: XNAS
Market: stocks
Locale: us
Currency: USD
Listed: 2012-12-18
Round lot: 100
Active: Yes
Last seen in a load: 2026-08-14 20:49
Vendor updated: 2026-08-13 06:09
Ticker root / suffix: PRTA

Detail

Enriched 2026-08-14 20:47

Market cap: $475,380,379.24
Shares outstanding (class): 52,353,237
Shares outstanding (weighted): 51,336,974
SIC: 2834 PHARMACEUTICAL PREPARATIONS
Employees: 67
Location: DUBLIN 2, L2
Homepage: https://www.prothena.com
Description: Prothena Corp PLC is a late-stage clinical biotechnology company that focuses on protein dysregulation and a pipeline of investigational therapeutics with the potential to change the course of devastating neurodegenerative and rare and peripheral amyloid diseases. Prothena is developing and applying its proprietary CYTOPE technology to target a broad spectrum of intracellular disease pathways in the brain and periphery. The company's pipeline includes both wholly-owned and partnered programs like Prasinezumab, Coramitug (PRX004), BMS-986446 (PRX005), PRX019, TDP-43 CYTOPE, and PRX012-TfR, being developed for the potential treatment of Parkinson's disease, ATTR amyloidosis with cardiomyopathy, Alzheimer's disease, Amyotrophic lateral sclerosis (ALS), and other neurodegenerative diseases.

Market cap and share counts drift.

Funds holding this security

85 funds · 85 positions · $48.32M reported value, as of 2026-03-31

All holders →

Fund	Ticker	Position value	% of fund	Balance	Match
iShares Russell 2000 ETF iShares Trust	IWM	$10.63M	0.01%	1,093,449 NS	TICKER
State Street(R) SPDR(R) S&P(R) Biotech ETF SPDR SERIES TRUST	XBI	$9.56M	0.13%	983,448 NS	TICKER
VANGUARD EXTENDED MARKET INDEX FUND VANGUARD INDEX FUNDS	VXF	$4.70M	0.01%	483,658 NS	TICKER
iShares Russell 2000 Value ETF iShares Trust	IWN	$3.30M	0.03%	339,557 NS	TICKER
VANGUARD STRATEGIC SMALL-CAP EQUITY FUND VANGUARD HORIZON FUNDS	—	$3.24M	0.13%	333,148 NS	TICKER
iShares Biotechnology ETF iShares Trust	IBB	$3.14M	0.04%	323,349 NS	TICKER
Bridge Builder Small/Mid Cap Growth Fund Bridge Builder Trust	—	$1.96M	0.02%	201,623 NS	TICKER
SMALL COMPANY GROWTH PORTFOLIO VANGUARD VARIABLE INSURANCE FUNDS	—	$1.02M	0.07%	105,240 NS	TICKER
Federated Hermes MDT Small Cap Value Fund f/k/a… Federated Hermes Equity Funds	—	$932.8K	0.62%	95,968 NS	TICKER
BlackRock Advantage Small Cap Growth Fund BlackRock Funds	—	$781.0K	0.12%	80,347 NS	TICKER
Master Small Cap Index Series Quantitative Master Series LLC	—	$641.8K	0.01%	66,028 NS	TICKER
SMALL CAP EQUITY FUND GuideStone Funds	—	$589.4K	0.07%	60,642 NS	TICKER
NVIT Multi-Manager Small Company Fund Nationwide Variable Insurance Trust	—	$572.4K	0.16%	58,890 NS	TICKER
Clearwater Select Equity Fund Clearwater Investment Trust	—	$525.2K	0.12%	54,034 NS	TICKER
NVIT Small Cap Value Fund Nationwide Variable Insurance Trust	—	$504.3K	0.27%	51,886 NS	TICKER

How positions resolve to the securities master. FIGI_COMPOSITE is exact identifier equality — both sides got the FIGI from Bloomberg. TICKER is a narrow fallback used only where the master row carries no FIGI at all (2,389 rows do not, disproportionately Irish-domiciled US listings like LIN and ACN). Roughly 22% of all positions resolve to the master.

This match is a candidate, not a mapping. N-PORT tickers are filer-entered free text and collide with delisted and foreign symbols. Only 13% of positions carry a ticker at all. Good enough to ask which funds report holding a symbol; not good enough to build exposure reporting on. Prefer the ISIN-resolved link, which is marked FIGI_COMPOSITE.

Funds holding this security

Identifiers

master.security_identifier

TICKERPRTA
CIK0001559053
ISINIE00B91XRN20
Resolved through OpenFIGI from a holdings ISIN, not supplied by the securities vendor.

Identifiers

Classification

classification.v_security_classification

Asset class: Equity
Sector: Health Care
Industry: Biotechnology
Source: LLMunreviewed
Self-reported confidence: 0.95
Model: deepseek
Rationale: Prothena is a clinical-stage biotechnology company focused on protein misfolding diseases, so it maps to healthcare/biotechnology.

Classifications are unreviewed model output. All 5,771 assignments carry source = LLM and is_reviewed = false. Confidence is the model’s own estimate and is not calibrated — it clustered at 0.90–0.98 across the whole first pass, including rows that later proved wrong. Use it to order a review queue, not as a probability. Two share classes of one issuer can disagree.

Classification

Fund data

Not linked to a fund series.

Either this is not a fund, or it is one the SEC share-class snapshot cannot reach — commodity trusts and notes have no series ID at all.